CD274 and neoplasm: Previous research has demonstrated that an AI-driven PD-L1 tumor ratio score-based analyzer can identify non-small cell lung cancer (NSCLC) more effectively than a pathologist can when predicting the immunotherapy response, and its results are objective and repeatable without human error (13).